Why Life Science CEOs Should Seize the Opportunity at Redefining Early Stage Investments (RESI) Events 

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

In the ever-evolving landscape of life sciences, fundraising is not just an option; it’s a necessity. CEOs in this sector must navigate a complex environment where access to capital can define the trajectory of their innovations. One of the most effective strategies for maximizing fundraising success is participating in global events that bring together key investors and decision-makers. The Redefining Early Stage Investments (RESI) events are premier platforms for life science startups. With RESI Boston on September 25, RESI London on December 4, and RESI JPM on January 14, 2025, this series presents a unique opportunity for CEOs.

The Importance of Global Reach

In the life sciences, the competition for funding is fierce, and operating within a confined regional market can limit opportunities. By expanding your search beyond local investors and tapping into the global arena, you significantly increase your chances of finding the right fit for your stage of development and innovative products. The RESI events are strategically designed to allow CEOs to engage with a diverse spectrum of investors from various geographic locations.

Attending both the Boston and London events and culminating with JPM in January allows you to cover critical markets—the East Coast of the U.S., Europe, and the West Coast—all within five months. This geographical breadth means you can connect with 50-60 qualified investors actively seeking investment opportunities in early-stage life sciences, increasing your chances of success.

Fundraising as a Numbers Game

At its core, fundraising is indeed a numbers game. The more potential investors you meet, the higher the likelihood of securing funding. The RESI events are structured to make sure you engage your outreach. With each event attracting a fresh group of investors, your networking efforts compound over time. This is unlike traditional fundraising approaches, where outreach may be static or limited to a single region.

Life Science Nation, the owner of RESI, has a proven track record of delivering diverse investors, ranging from angels and family offices to venture capitalists, private equity firms, and industry-specific players such as pharmaceutical and med tech investors. These investors increasingly leverage LSN’s global events to source new technology assets for their portfolios and product pipelines.

A Unique Lineup of Investors

The alignment of these three events within such a short period extends your reach and introduces you to an audience of investors tailored to your specific needs. The unique lineup of seasoned professionals at these events is precisely what early-stage companies require. This carefully curated access can distinguish between a successful fundraising round and an uphill battle.

CEOs in the life sciences sector must take advantage of the opportunities presented by the RESI events. Engaging with a global network increases visibility and access to critical funding sources. The following five months could very well determine the future trajectory of your company; make it count by attending RESI Boston, RESI London, and RESI JPM. The world of life science investment is waiting, and your next significant opportunity might be one conference away. Don’t miss your chance to take your innovations to the next level!